Changeflow GovPing Pharma & Healthcare Effect of Sildenafil on Left Ventricular Functi...
Routine Notice Added Final

Effect of Sildenafil on Left Ventricular Function in Pediatric Primary Dilated Cardiomyopathy

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registered observational study NCT07536880 titled 'Effect of Sildenafil on Left Ventricular Function in Pediatric With Primary Dilated Cardiomyopathy.' The study examines sildenafil's effect on left ventricular function in pediatric patients with primary dilated cardiomyopathy, characterized by left ventricular dilation and impaired contraction. The study was registered on April 17, 2026.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

NIH registered a new observational clinical trial (NCT07536880) evaluating sildenafil's effect on left ventricular function in pediatric patients with primary dilated cardiomyopathy. The study focuses on patients with impaired left ventricle fraction shortening less than 28% and left ventricular end diastolic dimension Z-score greater than 2, conditions that can lead to arrhythmias and sudden death.\n\nHealthcare providers and clinical investigators conducting or tracking pediatric heart failure research should note this study's registration. Pharmaceutical companies developing sildenafil or similar therapies for pediatric cardiomyopathies may find this relevant to their product pipelines. No compliance obligations or regulatory deadlines are created by this study registration.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Effect of Sildenafil on Left Ventricular Function in Pediatric With Primary Dilated Cardiomyopathy

Observational NCT07536880 Kind: OBSERVATIONAL Apr 17, 2026

Abstract

Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by left ventricular or biventricular dilation and impaired contraction that is not explained by abnormal loading conditions.(1) Both inherited predisposition and environmental factors play an important part in the natural history of disease.(1) Cardiomyopathies are group of heart diseases that influence cardiac muscles directly and are not related to hypertension, congenital, valvular and pericardial diseases. The most common type of cardiomyopathy is dilated cardiomyopathy (DCM).(2) Definitions of DCM provided by two major professional organizations (American Heart Association (AHA) and European Society of Cardiology (ESC)) Both organizations agreed that DCM could be clinically defined by the presence of left ventricular dilation and contractile dysfunction in the absence of abnormal loading conditions and severe coronary artery disease.(3) Dilated cardiomyopathy usually manifests as chronic systolic heart failure, which is detected by echocardiography as impaired left ventricle fraction shortening less than 28%, with left ventricular end diastolic dimension Z-score>2 ,leading to arrhythmias and sudden death.(4,5) idiopathic dilated cardiomyopathy (DCM) is characterized by dilatation and impaired contraction of the left ventricle or both ventricles, in the absence of underlying causes such as CAD, valve disease, congenital heart disease, or pericardial disease. Most patients present with symptoms of heart...

Conditions: Cardiomyopathy, Dilated

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 17th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07536880
Docket
NCT07536880

Who this affects

Applies to
Healthcare providers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Heart failure research Pediatric cardiology
Geographic scope
United States US

Taxonomy

Primary area
Public Health
Operational domain
Clinical Operations
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!